Literature DB >> 10203716

Immunotherapy with CTLs restricted by nonself MHC.

H J Stauss1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10203716     DOI： 10.1016/s0167-5699(99)01443-7

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


× No keyword cloud information.
  16 in total

1.  Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.

Authors:  Amy A Simpson; Fiyaz Mohammed; Mahboob Salim; Amy Tranter; Alan B Rickinson; Hans J Stauss; Paul A H Moss; Neil M Steven; Benjamin E Willcox
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.

Authors:  Hiroshi Fujiwara
Journal:  Int J Hematol       Date:  2013-12-19       Impact factor: 2.490

Review 3.  Exploiting T cell receptor genes for cancer immunotherapy.

Authors:  S Xue; R Gillmore; A Downs; A Tsallios; A Holler; L Gao; V Wong; E Morris; H J Stauss
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

4.  A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.

Authors:  Emma C Morris; Aristotle Tsallios; Gavin M Bendle; Shao-An Xue; Hans J Stauss
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-20       Impact factor: 11.205

Review 5.  Epidemiology and biology of relapse after stem cell transplantation.

Authors:  Mary Horowitz; Hans Schreiber; Alex Elder; Olaf Heidenreich; Josef Vormoor; Christina Toffalori; Luca Vago; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2018-04-18       Impact factor: 5.483

6.  Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype.

Authors:  Kyung Hee Noh; Young-Ho Lee; Ju-Hong Jeon; Tae Heung Kang; Chih-Ping Mao; T-C Wu; Tae Woo Kim
Journal:  Cancer Res       Date:  2012-02-14       Impact factor: 12.701

7.  In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy.

Authors:  J K Orleans-Lindsay; A Deru; J I O Craig; H G Prentice; M W Lowdell
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

8.  The vigor of defense against non-self: potential superiority of allorestricted T cells in immunotherapy of cancer?

Authors:  Stefan Burdach; Hans-Jochem Kolb
Journal:  Front Oncol       Date:  2013-05-03       Impact factor: 6.244

9.  NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

Authors:  Daniel Sommermeyer; Heinke Conrad; Holger Krönig; Haike Gelfort; Helga Bernhard; Wolfgang Uckert
Journal:  Int J Cancer       Date:  2012-09-14       Impact factor: 7.396

10.  Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.

Authors:  Shao-An Xue; Liquan Gao; Maryam Ahmadi; Sara Ghorashian; Rafael D Barros; Constandina Pospori; Angelika Holler; Graham Wright; Sharyn Thomas; Max Topp; Emma C Morris; Hans J Stauss
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.